Riyadh – Mubasher: Jana Medical Company has announced the commencement of the nomination period for membership in its Board of Directors for the upcoming four-year term, according to a bourse filing.
The new session is scheduled to begin on 28 July 2026 and conclude on 27 July 2030.
Shareholders and qualified professionals who meet the regulatory criteria set by the Saudi Capital Market Authority (CMA) and the company’s internal governance policies are invited to submit their applications within the designated window, which runs until 16 July 2026.
The upcoming board cycle will comprise seven seats, and the selection process will be conducted in accordance with the Saudi Companies Law and the Corporate Governance Regulations issued by the CMA.
Jana Medical emphasized that candidates must demonstrate the ability to provide strategic value and align with the company’s future growth objectives.
To ensure transparency and high standards of governance, the company has outlined a comprehensive set of eligibility requirements.
Prospective members must be at least 25 years of age and hold a minimum of a bachelor’s degree.
The company’s policy prioritizes candidates with professional competence, leadership skills, and specific expertise in sectors relevant to Jana Medical’s operations, such as medical maintenance, healthcare operations, administration, and financial analysis.
The nomination process requires the submission of several mandatory documents. These include a formal letter of intent addressed to the Board of Directors, a detailed curriculum vitae (Form 1 in both Arabic and English), and a signed copy of the CMA’s Form 3.
Applicants must also provide a disclosure of any potential conflicts of interest, including direct or indirect involvement in contracts or businesses that compete with Jana Medical.
Furthermore, candidates are required to list their current and previous board memberships in other joint-stock companies, ensuring they do not exceed the regulatory limit of five concurrent memberships in listed entities.
Jana Medical’s Governance and Compliance Department will be responsible for reviewing all applications. The Remuneration and Nomination Committee reserves the right to disqualify any application that is incomplete or fails to meet the established criteria without further notice to the applicant.
The final election of the board members will take place during a General Assembly meeting, the date of which will be announced following the receipt of necessary approvals from the relevant regulatory authorities.
The company also highlighted the criteria for independent members, noting that independence is compromised if a candidate owns 5% or more of the company’s shares, has served on the board for more than nine years, or has immediate family ties with board members or senior executives.
Per regulatory requirements, at least one-third of the board, or a minimum of two members, must be independent.
The opening of the nomination period marks a significant step in Jana Medical’s long-term governance planning, ensuring a structured transition for the 2026-2030 term.
By adhering to the cumulative voting system and stringent disclosure requirements, the company aims to maintain a board composition that reflects diverse expertise and robust oversight for its shareholders.
